Helen I. Torley
2016
In 2016, Helen I. Torley earned a total compensation of $4.9M as President and Chief Executive Officer at Halozyme Therapeutics, a 5% increase compared to previous year.
Compensation breakdown
Non-Equity Incentive Plan | $595,448 |
---|---|
Option Awards | $1,800,037 |
Salary | $645,000 |
Stock Awards | $1,799,998 |
Other | $9,592 |
Total | $4,850,075 |
Torley received $1.8M in option awards, accounting for 37% of the total pay in 2016.
Torley also received $595.4K in non-equity incentive plan, $645K in salary, $1.8M in stock awards and $9.6K in other compensation.
Rankings
In 2016, Helen I. Torley's compensation ranked 1,694th out of 14,075 executives tracked by ExecPay. In other words, Torley earned more than 88.0% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 1,694 | 88th |
Manufacturing | 577 | 90th |
Chemicals And Allied Products | 161 | 92nd |
Drugs | 110 | 93rd |
Biological Products, Except Diagnostic Substances | 22 | 92nd |
Torley's colleagues
We found four more compensation records of executives who worked with Helen I. Torley at Halozyme Therapeutics in 2016.
News
Halozyme Therapeutics CEO Helen Torley's 2021 pay rises 14% to $7.5M
March 25, 2022
Halozyme Therapeutics CEO Helen Torley's 2020 pay rises 11% to $6.5M
March 26, 2021
Halozyme Therapeutics CEO Helen Torley's 2019 pay rises 1% to $5.9M
March 20, 2020
Halozyme Therapeutics CEO Helen Torley's 2018 pay rises 12% to $5.8M
March 22, 2019